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Abstract
Recent advances in highly multiplexed immunoassays have allowed systematic large-scale
measurement of hundreds of plasma proteins in large cohort studies. In combination with
genotyping, such studies offer the prospect to 1) identify mechanisms involved with regula-
tion of protein expression in plasma, and 2) determine whether the plasma proteins are likely
to be causally implicated in disease. We report here the results of genome-wide association
(GWA) studies of 83 proteins considered relevant to cardiovascular disease (CVD), mea-
sured in 3,394 individuals with multiple CVD risk factors. We identified 79 genome-wide sig-
nificant (p<5e-8) association signals, 55 of which replicated at P<0.0007 in separate
validation studies (n = 2,639 individuals). Using automated text mining, manual curation,
and network-based methods incorporating information on expression quantitative trait loci
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(eQTL), we propose plausible causal mechanisms for 25 trans-acting loci, including a poten-
tial post-translational regulation of stem cell factor by matrix metalloproteinase 9 and recep-
tor-ligand pairs such as RANK-RANK ligand. Using public GWA study data, we further
evaluate all 79 loci for their causal effect on coronary artery disease, and highlight several
potentially causal associations. Overall, a majority of the plasma proteins studied showed
evidence of regulation at the genetic level. Our results enable future studies of the causal
architecture of human disease, which in turn should aid discovery of new drug targets.
Author summary
Several proteins that circulate in blood have been linked to cardiovascular disease through
the use of classic epidemiology and correlation studies. If individuals with higher risk of
disease have higher levels of a protein, the protein may be associated with disease. How-
ever, this does not necessarily mean that the protein causes disease; it may merely be an
innocent bystander or a consequence of the disease process. To establish whether a pro-
tein causes disease, a genetic approach, insensitive to reverse causation, can be used.
Instead of correlating the levels of the protein itself, gene variants that regulate the protein
levels are used in the analysis. This approach requires prior knowledge of which genetic
variants are linked to individual proteins. Therefore we completed a map of how common
genetic variants affect the blood concentration levels of 83 proteins that have been impli-
cated in cardiovascular disease. By using this map of cause-to-effect findings, we gained
insights into the regulation of a majority of the proteins under study and how they relate
to risk of coronary artery disease. This study provides a map of genetic regulation of
important cardiovascular plasma proteins, insights into their upstream regulatory envi-
ronment, as well as novel leads for cardiovascular drug development.
Introduction
Cardiovascular disease (CVD), especially coronary artery disease (CAD) is a leading cause of
human morbidity and mortality. Data from the World Health Organization (WHO) showed
that CVD caused approximately 17.5 million deaths in 2012, corresponding to 31% of all
deaths globally. Of these 7.4 million were estimated to be due to coronary heart disease and 6.7
million to stroke [1].
Specific and mechanistically relevant biomarkers are important tools in risk prediction, dis-
ease diagnosis and successful development of new therapies [2]. Proteins in the circulation
have been extensively explored as biomarkers across numerous disease conditions, not least
because of the relative ease with which blood plasma and serum can be accessed, stored and
analysed in observational studies and randomized controlled trials.
The usefulness of a plasma biomarker in disease prediction, or as surrogate endpoint in a
clinical trial, depends on its specificity and sensitivity. These metrics reflect the relationship of
the biomarker with a pre-specified disease endpoint, but are inherently influenced by biologi-
cal factors such as the tissue expression, stability, regulation and variability of the biomarker.
The genetic contribution to the variability of plasma biomarkers can be explored in genome-
wide association (GWA) studies using single nucleotide polymorphisms (SNPs), and this
approach has been applied to uncover numerous such relationships [3–5]. For distinct plasma
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biomarkers such as circulating proteins, the associations are also known as protein quantitative
trait loci (pQTLs) [6–9].
Genetic loci for biomarkers and pQTLs have wide applicability in research. Firstly, pQTLs
in trans can identify previously unknown regulatory pathways. Using trans-pQTLs to discover
regulatory pathways is beneficial because it is based on in-vivo human observations that have
well-established direction of causality, flowing from SNP to protein [7]. This approach has
been extensively used in-vitro, for example in yeast studies [8], and the overall goal of such
analysis is a deeper understanding of the regulatory check-points giving rise to a particular bio-
marker concentration. For a biomarker that is causally involved in disease, e.g. low-density
lipoprotein cholesterol (LDL-C), this is crucial knowledge as it allows targeting of upstream
factors, e.g. HMG-CoA reductase.
Secondly, GWA study loci associated with circulating levels of plasma biomarkers that are
predictive of disease risk enable evaluation of whether the biomarker association with disease
is likely to be a causal relationship, using Mendelian randomization (MR). For example,
although both C-reactive protein (CRP) and LDL-C predict risk of CVD and are lowered by
treatment with statins, MR studies have concluded that plasma LDL-C is an aetiologically
important factor, while plasma CRP is a biomarker that is not causally related to CVD [10,11].
Similarly, all efforts towards HDL-cholesterol lowering drugs have failed, consistent with MR
results showing that SNPs affecting HDL-levels are unrelated to risk of CVD [12]. Based on
these experiences of pharmacological treatment lowering the LDL-C concentration, one may
suggest that a biomarker which is both predictive and causal provides a more attractive target
for novel therapeutics. Numerous associations between biomarkers and disease have been
described in the literature, but the potential causal involvement of these biomarkers has only
been addressed for a limited number, partly due to a lack of robust genetic predictors for
many plasma proteins.
In the present study, we analyzed 83 plasma proteins using the Olink ProSeek CVD array in
3,394 European subjects with at least 3 established CVD risk factors. The majority of these pro-
teins are strong candidates for involvement in atherosclerosis, plaque rupture or thrombosis
and many are upregulated in CVD patients compared to controls or predict future risk of
CVD events, such as CAD. The proteins analysed included well-known candidates such as
interleukin-6, interleukin-18, CD40 ligand, and NTproBNP: a full list is available as supple-
mentary S3 Table.
The aims of the study were to i) identify genetic loci for circulating plasma proteins that
have previously been connected with CVD, ii) explore the mechanisms underpinning novel
loci by integrating genetics with other biological information and iii) apply the tools to test
causality in CAD.
Results
Of 83 proteins selected for known involvement in vascular disease and inflammation [13], we
observed 79 SNP-trait associations, consisting of 78 SNPs and their associations with 56 pro-
teins (Fig 1 and Table 1). Of the 79 associations, 41 were cis effects, where the index-SNP is
within 500 kb of the gene encoding the measured plasma protein. The functional effect at each
of these 41 loci is likely to be a direct effect either on the sequence of the plasma protein or on
regulatory variants proximal to the encoding gene. Additionally, we identified 38 trans effects,
all acting over distances more than 100 MB or at different chromosomes from the gene encod-
ing the associated protein. Both cis and trans findings represent new understanding of the
direct regulation of candidate CVD proteins, with trans findings additionally providing an
opportunity for new insight into regulatory pathways.
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We could replicate all but 6 of the pQTLs at nominal significance (P<0.05) in meta-analyis
performed in three independent cohorts (n = 2,639). All but 16 of the measureable pQTLs
were found to be reproducible at P<0.0007 (Bonferroni corrected value). An additional 8
pQTLs were not measured in the replication cohorts. All 79 SNP-trait associations are reported
in Table 1 along with indication of replication status. Detailed replication statistics is available
in supplementary S1 Table.
Finally we attempted to quantify the narrow-sense heritability explained from the measured
SNPs using Genome-Wide Complex Trait Analysis [14]. For 23 of the proteins, measured
SNPs explained 10% or more of the variability, but it should be noted that sample size imposes
limitations on these conclusions (supplementary S3 Table).
Protein quantitative trait loci acting in trans
For each of the reported trans associations, we evaluated the most likely cis-gene intermediary,
and investigated pathways in the direction of the plasma protein (Table 2). Cis-gene interme-
diary we define as a gene within 500 kb of the index SNP that is likely to be the first step in con-
veying the effect on plasma protein levels, according to the hypothesis that an effect on a
proximal gene is a likely first step.
Fig 1. Genome-wide association strength of all measured plasma proteins. The extent of each stack
indicates the negative log P of association between the plasma protein and SNPs. Stacks with black dots and
black text labels indicate cis-associations. Stacks with hollow circles and grey text labels indicate trans-
associations; their targets are indicated with central colour coded lines. Consequently, plasma proteins having
both cis- and trans-effects can be identified as those with a black dot stack as well as connecting lines from
hollow dots, e.g. XPNPEP2 or CCL4. Fully drawn circle shows P = 5e-8. Dashed circle shows 1e-15. A
detailed table of the genome-wide significant associations in this figure is available as supplemental S1 Table.
A zoomable and interactive version of this figure is available at www.olink-improve.com.
https://doi.org/10.1371/journal.pgen.1006706.g001
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Table 1. Overview of pQTL associations.
SNP id Trait -log(P) SNP id Trait -log(P)
Cis-acting loci Trans-acting loci
rs1580006‡ ADM 14.69 rs184243355* CCL3 7.65
rs2070600‡ AGER (RAGE) 9.52 rs73062378 CCL4 12.35
rs549596* BNP 13.76 rs62625034 CCL4 40.51
rs2188974 CCL3 17.31 rs28601761 CHI3L1 8.3
rs6607368 CCL4 30.2 rs200373 CTSL1 8.37
rs1569723 CD40 48.52 rs6993770 DKK1 8.79
rs2153101 CHI3L1 107.13 rs495828 F3 9.34
rs17610659 CSF1 9.19 rs200433550* F3 9.25
rs35285321 CSTB 42.93 rs1260326 FST (Follistatin) 8.69
rs111693235 CTSD 25.69 rs4672375 GAL 10.15
rs670211 CX3CL1 11.13 rs76519098† GDF15 9.95
rs74544699 CXCL1 11.88 rs693918 IL18 10.62
rs35186877 CXCL16 8.76 rs7599125‡ IL18 7.95
rs72650832 CXCL6 41.21 rs35166255 IL1RL1 8.93
rs982764 FAS 11.7 rs11599750 IL27 9.85
rs3195944 GDF15 7.65 rs10947260† IL6 9.74
rs6555820 HAVCR1 86.89 rs4810479 KITLG 10.35
rs13236526 HSPB1 16.96 rs7928577 LGALS3 8.67
rs139879640* IL16 61.53 rs1169306‡ LGALS3 8.19
rs75649625 IL18 20.84 rs33988101‡ LGALS3 8.45
rs1420101 IL1RL1 131.69 rs12570111† MMP1 7.33
rs4905 IL27 79.93 rs492602 MMP10 8.11
rs4129267 IL6R 264.67 rs12469459 MUC16 44.15
rs62115757 KLK11 61.91 rs61598054* NGF 7.42
rs11667946 KLK6 14.47 rs75416436† NGF 7.38
rs9323280 LGALS3 61.25 rs6557662* NPPB 7.83
rs471994 MMP1 34.63 rs140000161 PAPPA 9.84
rs17368659 MMP12 96.26 rs16873402‡ PDGFB 7.62
rs7946057 MMP3 107.92 rs635634 PECAM1 44.72
rs56378716 MPO 8.73 rs117538444† PGF 8.18
rs35207557* NPPB 24.59 rs635634 SELE (E-selectin) 219.02
rs880949‡ PGF 7.8 rs8176741 TEK 49.06
rs116661163 REN (Renin) 7.99 rs8176693 THBD 9.95
rs1969539 SPON1 21.82 rs241771‡ TNFRSF11B 9.22
rs79250370 TEK (TIE2) 12.71 rs142552223 TNFSF11 (TRANCE) 16.47
rs3176123 THBD 23.64 rs7813952 TNFSF11 (TRANCE) 15.67
rs6469811 TNFRSF11B (Osteprotegerin) 10.54 rs35538083† XPNPEP2 7.51
rs76769120‡ TNFRSF1B (TRAIL) 10.87 rs11150189‡ XPNPEP2 13.16
rs344560 TNFSF14 17.53
rs2050011* XPNPEP2 67.62
rs2271025 AGRP 8.63
More commonly used non-systematic names indicated in parenthesis for some proteins.
* pQTL that was not measured in replication cohorts,
† pQTL that was measured in replication cohorts, but did not replicate at P<0.05,
‡ pQTL that did not replicate at Bonferroni corrected value of P<0.0007.
A more detailed version of this table is found as supplemental S1 Table.
https://doi.org/10.1371/journal.pgen.1006706.t001
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Table 2. Systematic analysis of potential mechanisms behind trans-pQTL associations.
trait-
protein
SNP cis-gene Distance
(kb)
Dist-
rank
Coding-proxy Cis-eQTL Un-
weighted-
pathway
eQTL-weighted-
pathway
Literature-
score
CCL4 rs62625034 CCR5 0 1 rs62625034
(R2 = 1)
59
CTSL1 rs200373 IFI30 0 1 Monocytes+LPS
(P = 2.6e-05),
Monocytes+IFN
(P = 1e-04)
MAST3 24 5 rs8108738 (R2
= 0.64)
F3 rs495828 SURF6 43 2 Monocytes (P = 2.9e-
05), B-cells (P = 3.4e-
05)
MED22 53 3 Via PPARD
(P = 0.00321)
FST rs1260326 GCKR 0 1 rs1260326 (R2
= 1)
KRTCAP3 62 4 B-cells (P = 3.4e-08)
GDF15 rs76519098 MAPK8 283 4 Yes Yes, short
IL18† rs693918 XDH -231 3 Via TLR4
(P = 0.00085)
IL18 rs7599125 LTBP1 -311 3 Via TGFB2
(P = 0.00321)
NLRC4 -371 5 Yes Yes, short
IL1RL1 rs35166255 TIRAP 137 4 Yes Yes, short
RPUSD4 -220 8 Monocytes+IFN
(P = 0.00034)
IL27 rs11599750 CWF19L1 187 6 4 eQTL-sets show cis-
eQTL effect
IL6‡ rs10947260 BTNL2 0 1 rs60263670
(R2 = 1)
NOTCH4 -181 6 Via CCND1
(P = 0.00427)
AGER -221 9 64
ATF6B -277 18 Via ATF3
(P = 0.00349)
KITLG rs4810479 PLTP -4 1 Liver (P = 4.2e-09), B-
cells (P = 4.3e-07)
PCIF1 -18 3 Monocytes+IFN
(P = 5.4e-05)
ACOT8 -59 9 Monocytes+IFN
(P = 0.00021)
MMP9 -92 12 Yes Yes, short
LGALS3 rs7928577 TIRAP 63 3 Via IL6
(P = 0.000463)
CDON -295 9 Via CTNNB1
(P = 0.00494)
LGALS3 rs1169306 HNF1A 0 1 rs2464196 (R2
= 0.71)
C12orf43 3 2 5 eQTL-sets show cis-
eQTL effect
LGALS3 rs33988101 RASIP1 6 2 rs2287922 (R2
= 0.88)
(Continued )
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Table 2. (Continued)
trait-
protein
SNP cis-gene Distance
(kb)
Dist-
rank
Coding-proxy Cis-eQTL Un-
weighted-
pathway
eQTL-weighted-
pathway
Literature-
score
FUT2 9 3 rs602662 (R2
= 0.68)
FGF21 -41 6 Via EGFR
(P = 0.000853)
BCAT2 80 10 Via GAPDH
(P = 0.000584)
MMP10 rs492602 FUT2 0 1 rs601338 (R2
= 0.99)
RASIP1 17 3 rs2287922 (R2
= 0.68)
PPP1R15A -169 18 Via GADD45A
(P = 0.0045)
BAX -252 26 Via TNF
(P = 0.00461)
MUC16 rs12469459 GAL3ST2 0 1 rs12469459
(R2 = 1)
D2HGDH 8 2 Monocytes (P = 9.6e-
06)
NGF* rs61598054 FOXO3 -70 2 Via AKT1
(P = 0.00376)
PAPPA rs140000161 PRG2 0 1 Monocytes+IFN
(P = 5.4e-06)
Yes Yes, short
PECAM1 rs635634 SURF6 43 2 B-cells (P = 1.7e-05),
Monocytes (P = 3.3e-
05)
SELE rs635634 SURF6 43 2 B-cells (P = 1.7e-05),
Monocytes (P = 3.3e-
05)
MED22 53 3 Via PPARD
(P = 0.00277)
TEK rs8176741 ABO 0 1 rs8176747 (R2
= 0.98)
MED22 76 5 Via ALB
(P = 0.00266)
RPL7A -84 6 Via UBC
(P = 0.000421)
GBGT1 -92 9 Via ALB
(P = 0.00266)
THBD rs8176693 ABO 0 1 rs8176746 (R2
= 1)
TNFSF11 rs7813952 TNFRSF11B -159 3 Yes Yes, short 626
For each of 41 SNPs that had an effect in trans, cis-genes within 500 kb were analysed using 5 different methods for evaluation of mediator cis-gene: 1)
presence of non-synonymous coding SNP in LD with index SNP at R2>0.6, 2) presence of FDR5% cis-eQTL effect, 3) presence of significant pathway to
trait-gene shorter than 95% of randomly permuted pathways, 4) presence of eQTL-weighted pathway to trait-gene shorter than 95% of randomly permuted
pathways and/or 5) literature matching score above 50. A total of 1618 SNP-cis-gene pairs were considered, but only pairs that satisfied at least one of the
tests are shown.
* Fig 2A,
† Fig 2B,
‡ Fig 2D.
https://doi.org/10.1371/journal.pgen.1006706.t002
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Analysis of coding proxies revealed that 10 trans loci had missense mutations in linkage dis-
equilibrium (LD) with the index-SNPs, providing an obvious explanatory model for a cis-gene
intermediary mechanism of action.
The analysis of cis-eQTLs in 11 large cardiovascular eQTL data sets provided evidence for
an additional 13 mediator cis-genes. The basic eQTL analysis investigates if the expression of a
gene is associated with the genotype of a proximal index SNP, and is motivated by common
cases of cis-genes not being the gene closest to the index SNP [15,16]. Some of the findings
were remarkably independent of tissue and cell-type, and showed concordant results in several
of the 11 eQTL datasets under analysis, as indicated in Table 2. At each locus with significant
cis-eQTL association, we additionally investigated neighbouring eQTL and pQTL effects as
LocusZoom plots (supplementary S2 Fig). In some cases, like rs4810479/KITLG, the index-
SNP shows both the strongest association with KITLG and the strongest cis-gene association
(PLTP in liver). However, cases also exist, like rs200373/CTSL1, where stronger eQTL effects
for the candidate cis-gene intermediary exists from other SNPs, with low LD between the
SNPs precluding straightforward interpretation. Further studies would be required to address
this issue.
In pathway analysis using the String-database of protein interactions, an additional 6 trans-
genes were highlighted as possible mediator genes through functional protein connections.
The criterion in this analysis was that less than 5% of randomly re-wired networks had shorter
distance, dictating simply that connections of length 1 from a cis-gene to the trait gene should
be selected. Additionally, a more sophisticated weighted network analysis was performed
where each path through the network was weighted by the strength of the (trans) eQTL of the
index-SNP. The eQTL values were calculated using a large collection of eQTL databases with
tissues and cells relevant to cardiovascular disease. Like in the unweighted network analysis
permutation was used to determine significance threshold. Through this weighted network
analysis approach we discovered 11 additional mediator candidates, examples being the
rs61598054 -> FOXO3 -> AKT1 -> NGF and the rs693918 -> XDH -> TLR4 -> IL18 that are
illustrated in Fig 2A and 2B.
Systematic literature mining suggested an additional 5 possible mediators. Co-occurrence
in scientific abstracts can indicate real biological relationships that may be missing from the
String network. Interestingly, across all trans-pQTL loci, the largest number of abstract co-
occurrences was 626 for the receptor-ligand pair encoded by TNFSF11 and TNFRSF11B, a
protein-protein interaction also reported in String-db.
The results of these five cis-gene mediator approaches are summarised in Table 2. While
examples given above provide relatively clear indications of trans mechanism, more challeng-
ing cases do exist: several strong SNP-protein associations gave no evidence of pathway or cis-
gene intermediary, including the disease-relevant rs16873402 -> -> -> PDGFB association.
Clearly alternative non-obvious mechanisms must be responsible for these. Other findings
gave vague and discrepant results, such as the rs10947260 -> -> -> IL6 association, which
pointed to several candidate cis-mediator genes: BTNL2, NOTCH4, AGER, and ATF6B, each
with different types of evidence and in the context of non-significant replication for this SNP-
protein association (Fig 2D). We conclude that in all these cases further experimentation is
required to establish the main mechanism in this case.
Pleiotropy of loci affecting protein levels
Inspection of potential pleiotropic effects of index SNPs on measured protein traits as
described in Methods revealed 6 distinct candidate loci (supplemental S1 Fig). The ABO
locus affecting THBD, TEK, F3, PECAM1, and SELE in our dataset and the FUT2 locus
Novel loci for the plasma proteome
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Fig 2. String-database network connections between proximal cis-gene and target plasma protein. All short String paths that
connect proximal cis-genes with the target plasma protein are shown. The colour intensity of each gene shows the eQTL association-
strength with the index-SNP. The nodes highlighted with bold border show paths that satisfy P<0.05 in network permutation analysis. A) the
rs61598054-SNP is harboured in an intron of the LACE1 gene, but have no paths to the target gene NGF and a more likely mechanism is
therefore FOXO3 -> AKT1 ->NGF, which involves a rs61598054-trans-eQTL effect on AKT1. In permutation analysis of re-wired networks
this is stronger than 95% of random networks. B) Similarly for rs693918, while located between SRD5A2 and MEMO1, the path XDH ->
Novel loci for the plasma proteome
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affecting MMP10, F3, and LGALS3 are well known for their pleiotropic effects [17]. Further-
more, all SNPs affecting BNP levels seem to also impact NPPB levels. This likely indicates an
effect on steps before cleavage of the precursor protein. NTproBNP is a prohormone with an
inactive N-terminal part that is cleaved to produce the active BNP. However, because of its
half-life NTproBNP is typically used as a prognostic biomarker. A locus within the ZFPM2
gene seems to have a strong effect on PDGFB, DDK1, and, to a lesser extent, on VEGFA.
Finally, the cluster of cis-acting variants in the MMP1, MMP3, and MMP12 loci are not spe-
cific to only one of the proteins but seem to impact all three of the metalloproteinases in this
genomic region.
Additionally, we investigated the known associations of the index-SNPs with a broad range
of other phenotypes, as previously reported in literature (supplemental S2 Table).
Associations between plasma proteins and cardiovascular risk
To assess a potential causal involvement of each protein in CAD, we calculated genetic risk
scores from the publically available CARDIoGRAMplusC4D GWAS data with the aim to con-
struct a more powerful genetic instrument for those markers for which there were multiple
SNPs. First, a systematic look-up of all reported pQTL-SNPs was performed to test for associa-
tion with CAD (Table 3). Then, we further explored proteins with multiple independent loci
by calculating pooled SNP scores per protein, thus creating more powerful instruments to
TLR4 -> IL18 is a more likely mechanistic path, supported by eQTL effects on both XDH and TLR4. C) The rs61598054-AKT1 trans-eQTL
from panel A in 235 IFN-stimulated monocytes and the rs10947260-ATF3 trans-eQTL from panel D in 89 mammary artery samples. D)
Example of ambiguous findings regarding the rs10947260 -> -> -> IL6: The SNP has a coding-proxy in BTNL2, literature mining evidence for
the AGER gene, but also eQTL-weighted pathway evidence for both ATF6B and NOTCH4.
https://doi.org/10.1371/journal.pgen.1006706.g002
Table 3. Association between pQTLs and Coronary Artery Disease (CAD) risk. Each SNP from supplemental S1 Table was investigated in the CARDIo-
GRAMplusC4D data, and the P-values for the pQTL and CAD risk were extracted. An additional pooled analysis was performed in cases where one plasma
protein had multiple pQTLs,. The table shows all pQTLs for which either a single-SNP or pooled CAD association had a P<0.05. P-values highlighted in italics
indicate that the association was also significant after FDR correction for multiple testing.
SNP Trait-protein Cis / trans Pprotein βCAD PCAD βCAD-pool PCAD-pool
rs635634 PECAM1 trans 1.9E-45 0.08 4.47E-11
rs635634 SELE trans 9.6E-220 0.08 4.47E-11
rs495828 F3 trans 4.5E-10 0.07 1.29E-10
rs4129267 IL6R cis 2.1E-265 0.05 2.21E-07
rs28601761 CHI3L1 trans 5.1E-09 0.05 1.00E-06 0.03 2.3E-05
rs1169306 LGALS3 trans 6.5E-09 0.03 5.69E-04 0.02 5.9E-05
rs7928577 LGALS3 trans 2.2E-09 0.06 1.28E-03 0.02 5.9E-05
rs17368659 MMP12 cis 5.5E-97 0.05 1.39E-03
rs16873402 PDGFB trans 2.4E-08 0.03 1.47E-03
rs6993770 DKK1 trans 1.6E-09 0.03 6.90E-03
rs880949 PGF cis 1.6E-08 0.02 2.00E-02 0.02 2.0E-02
rs17610659 CSF1 cis 6.5E-10 0.02 2.25E-02
rs112579976 CCL4 trans 2.5E-13 0.05 3.03E-02
rs9323280 LGALS3 cis 5.6e-62 0.02 3.20E-01 0.02 5.9E-05
rs2153101 CHI3L1 cis 7.5E-108 0.01 4.68E-01 0.03 2.3E-05
rs33988101 LGALS3 trans 3.6E-09 0.01 5.16E-01 0.02 5.9E-05
rs117538444 PGF trans 6.5E-09 0.01 7.64E-01 0.02 2.0E-02
https://doi.org/10.1371/journal.pgen.1006706.t003
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analyze the causality for proteins with multiple SNPs. Results show that of the SNPs contribut-
ing to the concentrations of proteins (Table 1), eight were also significantly associated with
risk of CAD at FDR corrected significance levels (Table 3). These findings suggest a causal role
for these proteins, and whilst the cis IL6R finding confirms previous observations [18], the
other observations extend our knowledge of important factors in CVD. Results from pooled-
scores include highlights such as the multi-SNP support of LGALS3 and the contradiction of
CHI3L1 having a CAD-associated trans-effect but no CAD-association in the cis-loci (Table 3
and data from [19]).
Discussion
In this study, we identified 79 pQTLs by measuring 83 plasma proteins of cardiovascular inter-
est in a cohort of 3,394 subjects with multiple risk CVD risk factors, which may increase the
power to detect genetic variants associated with CAD-associated proteins. The study provided
novel insights into 57 of the plasma proteins under investigation, including cis- and trans
genetic regulation and effects of long-distance regulation networks and tentative evidence for
causal involvement in CVD.
To the best of our knowledge only a few of the findings were previously known; however
reassuringly these replicated as expected: IL18/rs75649625 and rs4129267/IL6R [20], as
well as AGER/sRAGE, CD40 and LGALS3 cis associations [17,21,22] and the rs8176741/
TEK trans association [23], and the rs635634/SELE [24]. In contrast, six of the 79 pQTLs
did not replicate. There are several explanations for the lack of replication, with the most
important being differences between the IMPROVE study and the replication studies
PIVUS/ULSAM and NSHPS. The replication studies were smaller which may have led to
insufficient statistical power to detect association, and the IMPROVE study included a high
proportion of patients with diabetes, high blood pressure, high cholesterol and high body
mass index. We cannot exclude the possibility that some pQTLs interact with disease
status.
Of the 79 pQTLs detected in the present investigation, 16 (20%) explained more than
5% of the total protein level variability, and another 11 over 2%. With two exceptions, the
pQTLs explaining more than 5% of the variability appeared to be cis-acting, which high-
lights the importance of proximal regulatory mechanisms. This observation suggests that
large sample sizes will be needed to detect trans-acting pQTLs. This was also the conclusion
reached when trying to quantify narrow-sense heritability for all proteins (supplementary
S3 Table).
Whilst recognizing that human complex traits have different genetic architectures, are not
equally easy to accurately measure, and that the proteins investigated in the present study may
not be representative for other plasma proteins, our observations suggest that the relative
importance of SNPs for circulating proteins is on average greater than for other biochemical
traits. For example, the R46L variant in the PCSK9 gene explained 1.19% of the LDL-C vari-
ability in a fine-mapping experiment involving over 10,000 subjects. In the same report it was
shown that a combination of all the 8 lead SNPs for LDL-C association explained only 7.1% of
the variability [25]. One may speculate that since many of the proteins found in circulating
blood exist in both membrane-bound and soluble forms, because of alternative splicing or
active shedding, SNPs acting in both cis- and trans play a significant role in these processes.
Ultimately, systematic mapping of pQTLs for a wider range of human proteins in large sam-
ples and in other matrices such as urine, cerebrospinal fluid or whole-cell lysates from biopsy
material, followed by functional experiments, are needed to elucidate genetic regulation of the
human proteome.
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Insights into specific trans-effects
A proteomics GWA study provides an interesting opportunity for the study of trans-regulatory
effects, because the trait is a well-defined biological entity. In some cases, the trans-pQTL
investigating methods in Table 2 converged on a very plausible candidate gene. For example,
at the CCL4-rs62625034 locus the effector transcript is probably the CCR5 gene, while at the
TNFSF11-rs7813952 locus, the effector transcript is likely the TNFRSF11B gene, two examples
of known ligand-receptor pairs. Another example is the IL27-rs4905 variant, which sits within
the EBI3 gene. The IL27 and EBI3 genes encode the two subunits of the IL27 cytokine
complex.
The effector transcript at the KITLG-rs4810479 locus may be MMP9, which encodes a
metalloproteinase that cleaves the KITLG gene product, a membrane-bound stem cell factor
[26]. Thus this trans pQTL may represent an example of genetic regulation via post-transla-
tional modification.
At a few loci, we found either nothing or multiple lines of evidence suggesting different
mediator genes at the same locus. This is not biologically impossible, nor is it uncommon in
the literature [27], but it does require more careful analysis. The challenge is illustrated by the
IL6-SNP rs10947260, for which separate lines of evidence pointed to three candidate cis-medi-
ator genes. As shown in Fig 2D, a criticism against concluding on the importance of a pathway
to IL6 through the CCND1 gene is that NOTCH4 has many neighbours in the String-network,
thereby increasing the risk of a spurious discovery.
While these examples seem specific, they illustrate challenges that have major consequences
for the general interpretation of any genetic association result. Analyses such as these have
driven the development of popular risk-gene assignment tools (e.g. [28]). Our findings illus-
trate the increased power of knowing a certain pathway destination through the use of pQTL.
Insights into potential causal involvement of the plasma proteins in CVD
The study provided an important opportunity to systematically test each of the plasma proteins
for a potential causal role in CVD by investigating whether identified pQTLs also were associ-
ated with CAD risk. If an instrumental variable, e.g. a SNP or a set of SNPs, exclusively affects
one factor, and also affects an overall phenotype, such as disease risk–then it may be deduced
that the protein is causally involved in the development of this disease. According to this prin-
ciple, eight proteins (PECAM1, SELE, F3, IL6R, CHI3L1, LGALS3, MMP12, and PDGFB)
showed evidence of potentially causal involvement in CAD. The connection between IL6R and
CAD has already been described [18], and several drug trials are underway to test whether an
ILR6-inhibitor (tocilizumab) is effective in treatment of CAD (clinicaltrials.org). In light of
this, the remaining proteins could be of interest as therapeutic targets.
However, there are some important limitations to the approach, as compared to a formal
MR. A formal MR study requires that the genetic instrument is specific, is not in LD with
other functional variants, and that there are no hidden population strata [29]. There is no rea-
son to suspect that the second and third requirements were violated; the study was based on
high-resolution imputation of cohorts that were ethnically homogeneous. Importantly, the
specificity requirement was not always satisfied, weakening the findings for some proteins.
This includes all the trans associations, as well as proteins for which pleiotropy was detected
(supplemental S1 Fig and supplemental S2 Table). In addition, association between plasma
protein concentrations per se and future CVD risk has not been carefully investigated for the
majority of proteins included in the present study.
These limitations leave LGALS3, MMP12 and PDGFB as candidates for having a causal
effect on CAD. Of the three SNPs affecting levels of LGALS3, rs1169306, rs7928577 and
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rs33988101 in trans, only the first two also contribute to CAD risk, resulting in a pooled CAD
association P-value of P = 1.46e-4. For MMP12 and PDGFB, the results are based on single
SNPs showing associations with protein levels. Of the three, only MMP12 is a cis effect thereby
strengthening the case for it being a specific MR instrument. These limitations notwithstand-
ing, the map of pQTLs presented here, and in particular those acting in cis, should provide the
means to systematically assess potential causal roles of these biomarkers in other common
complex diseases. Additionally, we highlight the online resource found at www.olink-improve.
com where the data pQTL can be browsed in greater detail. This may in turn help to prioritise
drug targets for development of disease-modifying therapies.
Conclusion
In conclusion, the main contributions of this paper are: i) identification of 79 pQTLs regulat-
ing important circulating cardiovascular plasma proteins, ii) novel evidence of the regulatory
mechanisms underpinning at least half of these novel loci and iii) evidence of potential causal
roles in CAD development for several plasma proteins. We believe that these three principal
findings provide a strong contribution to the field of cardiovascular biomarkers and beyond.
Materials and methods
The IMPROVE study
The IMPROVE study is a multicentre, observational study, which recruited 3,711 men and
women aged between 55 to 79 years with at least three cardiovascular risk factors but without
symptoms of CVD (previously described [30]). Serum and plasma from the study participants
were collected at baseline, dispensed in polypropylene tubes and frozen at –80˚C prior to ship-
ment for centralized biochemical analyses and biobanking at the Karolinska Institutet in
Stockholm, Sweden. The study was conducted in accordance with the declaration of Helsinki
and all participants gave written informed consent. The individuals in the discovery cohort,
IMPROVE, were recruited in 7 different centres in Finland, France, Italy, the Netherlands,
and Sweden. The relevant permits were given by ethical committees for each the 7 different
centers as follows: Kuopio Research Institute of Exercise Medicine, Finland. Kuopio University
Hospital, Finland. Karolinska Institute, Stockholm. University Medical Center Groningen,
Groningen, the Netherlands. Groupe Hospitalier Pitie´-Salpe´trière, Unite´s de Pre´vention Car-
diovasculaire, Paris, France. Dipartimento di Scienze Farmacologiche e Biomolecolari, Milan.
University of Perugia, Italy. The ethics and sampling of this cohort have been further docu-
mented in prior publications, e.g. [33]. The individuals in the replication cohorts, NSPHS,
PIVUS and ULSAM were likewise recruited following informed written consent. The relevant
permits were all given by the regional ethics committee at Uppsala University, Sweden. The
ethics and sampling of these cohorts have been further documented in prior publications
[31,32].
Genotyping, quality control and imputation
DNA genotyping in the IMPROVE study was performed using the Illumina CardioMetabo-
chip and Immunochip arrays. The combined SNP genotyping data from both platforms were
merged and subjected to the following quality control (QC) using PLINK 1.7: SNPs were
excluded for probe to genome mismatch, incorrect assignment of allelic variants in the array
design, failed Hardy-Weinberg Equilibrium test at 1x10-6, call rate<95% or failed Illumina
genotype calling QC. Samples were excluded if they showed evidence of gender mismatch,
abnormal inbreeding coefficient, failed cryptic relatedness test or had an overall sample call
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rate<95%. After quality control, a total number of 3,394 subjects remained for analysis. Impu-
tation was performed with MACH 1.0 algorithm with 1000 genomes CEU v3 as reference
panel. The pre-imputation data set contained 244,814 SNPs and the post-imputation data set
contained 5,270,624 SNPs.
Plasma protein determinations and quality control
In total, there were 3,394 IMPROVE participants for whom quality controlled genotype infor-
mation and plasma samples were available. Plasma concentrations were measured in baseline
EDTA plasma samples using the ProSeek CVD array I (Olink Biosciences, Uppsala, Sweden),
according to the standard protocol. The ProSeek method is based on the highly sensitive and
specific proximity extension assay (PEA), which involves the binding of distinct polyclonal oli-
gonucleotide-labelled antibodies to the target protein followed by quantification by real-time
quantitative PCR [13]. In addition to the controls provided by Olink Biosciences, a pooled
plasma control was included in all plates to enable further quality control (QC) such as calcula-
tion of variation coefficients. Prior to statistical analyses, we excluded individual assays with
more than 20% of samples below the lower detection limit and those with final inter-plate coef-
ficients of variation above 25%. After QC, a total number of 83 proteins out of the 92 remained
for analysis (full overview in supplementary S3 Table). The native scale of Olink protein mea-
surements is log(2) but additional log(10) transformations were performed to ensure normally
distributed variables. Overview of standard curves for all proteins are given in supplemental S1
Dataset. Validation of the OLINK method has been conducted [13], and the method has been
used to validate previous findings obtained with established protein quantification methods
[31,34].
Genome-wide quantitative trait locus discovery
Plasma protein readings were log10 transformed prior to analyses. Standardized residuals for
each of the 83 plasma proteins were calculated using a linear model adjusting for age, sex,
recruitment centre, protein analysis batch, smoking, diabetes and hypertension at baseline. To
merge loci in Table 1 and supplementary S1 Table, signals with R2 higher than 0.1 and distance
within 250 KB were omitted, retaining only the strongest signal in each block, referred to as
the index SNP. The standardized residuals were used in a Wald-test in PLINK 1.9 to test asso-
ciation between genetic data and each plasma protein, using a significance threshold of
P< 5e-8. All summary statistics can be downloaded at www.olink-improve.com, or from the
Zenodo data-repository (DOI 10.5281/zenodo.264128).
Narrow-sense heritability for all proteins was calculated using Genome-Wide Complex
Trait Analysis [14]. A genetic relationship matrix was calculated using all measured autosomal
SNPs with, less than 1% missingness and allele frequency above 5%, using the restricted maxi-
mum likelihood analysis (REML). Attempts at quantifying heritability using imputed data
failed for 37 of 83 measured proteins.
Replication of pQTL effects
Replication studies of all pQTLs were performed in three community-based cohorts in which
Olink array protein data and genotypes were available. These cohorts were the NSPHS [32],
the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) and the Uppsala
Longitudinal Study of Adult Men (ULSAM) [31], consisting of samples from 976, 933 and 730
participants, respectively. Statistics were calculated according to additive association models,
and findings were matched either directly on imputed SNP-id (96% of cases) or using a proxy
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with R2 > 0.8 linkage disequilibrium. Replication P-values were calculated using the METAL
meta-analysis software (version 2011-03-25).
Expression quantitative trait analysis
For each index-SNP, cis- and trans-eQTL data were calculated from the following sources:
aorta intima-media, aorta adventitia, liver, mammary artery, and heart from the ASAP study
[35], monocytes and B-cells from the Fairfax et al study [36], and monocytes stimulated with
LPS-2h, LPS-24h and interferon-2h from another Fairfax et al study [37]. Each of these 11
data sets had information from gene expression microarrays and genotyping microarrays as
described in the respective references. The mean sample size was 223 with a range of 89–
367. Data from genotyping microarrays were imputed using the MACH 1.0 algorithm with
1000 genomes CEU v3 data as reference (mean rsq quality score 0.89) [38]. The strength of
eQTL association was calculated using a linear additive model between log2-transformed
expression value and numerically encoded genotype data. For cis-eQTL associations, un-
corrected p-values from cis-eQTL were reported if the association was stronger than
P < 0.0005 (corresponding to a false discovery rate (FDR) <5%). For all significant cis-
eQTL associations, locusZoom plots were generated showing regional effect differences
between eQTL and pQTL studies [39].
Network analysis
The network analysis was performed based on the String database network (version 10) [40],
using all edges with a confidence score above 400. For all genes within 0.5 MB of an effect-SNP
(“cis-genes”), the shortest path length was calculated between the cis-gene and the gene encod-
ing the measured protein biomarker (“trait-gene”) using the igraph package in R (version
1.0.1). This was done both with an unweighted version of the Stringdb-network as well as with
a weighted version, wherein each gene along the path was weighted by the trans-eQTL strength
calculated from the effect-SNP (scored as 1, except if PeQTL < 0.05 which gave score 0.8, and if
PeQTL < 0.005, which gave score 0.6).
For both weighted and unweighted networks, significance of a path was calculated as the
fraction of 1000 randomly permuted networks that obtained a shorter path length than the
one tested. Random networks were generated using permutation of the original scores and
random rewiring of the network using the igraph rewire function, as detailed in code reposi-
tory http://github.com/lassefolkersen/olink-improve. Given our data, only paths of length 1,
i.e. direct links in String-db, were significant at a 0.05 level in the unweighted case. For the
weighted case, only paths of length 2 with an intermediate trans-eQTL gene reached signifi-
cance. Paths were subsequently checked for biological plausibility.
Literature analysis
To support the assignment of potential causal genes in pQTLs, we mined the literature for top-
ical co-occurrences of each gene in a pQTL (defined by a window extending 500kb in both
directions) with its associated protein. The Pfizer-internal LitMS tool can provide such
matches based on all PubMed abstracts, a large synonym dictionary and manually curated
rules that limit findings to more relevant articles, e.g. those in which gene and protein occur in
the abstract’s title. The system outputs the number of co-occurrences and underlying article
references for each gene-protein input pair. We then reviewed the literature findings to assign
the most plausible causal genes where possible.
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Pleiotropy
To understand the specificity of all reported index-SNPs we inspected all index SNPs that had
at least 2 associations with distinct proteins at P<0.05 / (83 79) = 7.7e-6. This cutoff reflects a
conservative approach to the multiple testing burden for all identified index SNPs (79) with all
tested protein traits (83). The resulting association matrix was then clustered and visualized
based on the negative log10 of the p-values of association. For the clustering, we used a com-
plete-linkage hierarchical clustering approach based on the negative log10 of the p-values with
Pearson correlation coefficients as a metric. In addition, index-SNPs were investigated for
other associations in publically available GWAS databases.
Calculation of genetic risk scores
To assess the effect on disease, the publicly available CARDIoGRAMplusC4D 1000G imputed
data was interrogated [19]. The goal was to perform in silico analysis for every SNP that
showed significant associations with any of the measured traits. For traits that had multiple
associated SNPs, pooled scores per affected protein were calculated using the R-package gtx
version 0.0.8. Specifically for the pooled risk scores, the alleles of each protein were encoded so
that the coded allele was increasing CAD risk regardless of its protein concentration effect.
This ensured that pooled effect sizes reflected uniform directionality on CAD risk.
Supporting information
S1 Fig. Potential pleiotropy between genome-wide significant SNPs and measured trait
proteins. This figure shows all lead SNPs that have at least 2 associations with distinct proteins
at P<0.05 / (83 79) = 7.7e-6. This cutoff reflects a conservative approach to the multiple test-
ing burden for all identified lead SNPs (79) with all tested protein traits (83). Protein traits are
not displayed if they have no associations with the selected SNPs at the defined threshold. Red
colour indicates the main effect as reported in S1 Table. Grey-scale colours indicate the effect
strength on a–log10(P) scale as indicated.
(PDF)
S2 Fig. LocusZoom plots of eQTL and pQTL effects, for each locus with significant cis-
eQTL association according to Table 2.
(PDF)
S1 Table. Overview of all associations between plasma protein and SNPs significant at
genome-wide level. Trait–the plasma protein target; Dist (kb)–if cis, the distance between
SNP and protein encoding gene; Likely mediator gene–the most likely cis-mediator gene. In
cis-cases protein-encoding gene, but in trans-cased based the analyses presented in Table 2;
Discovery P–the pQTL association P-value from the Olink-Improve discovery cohort
(n = 3,394); Discovery Beta–the Olink-Improve effect size; R2 –proportion of the protein level
variance that is predictable from genotype; A1/A2 –encoded allele and alternative allele; A1
freq–frequency of encoded allele; Imputation quality–the Rsq imputation quality score
(MACH 1.0); Protein name; Replication P—the pQTL association P-value from the replication
cohorts (n = 976, n = 933,n = 730); Combined P–the meta-analysis P-value of both discovery
and replication; Directions—for replication meta-analysis are indicated as IMPROVE (discov-
ery), NSPHS (replication), ULSAM-PIVUS (merged replication). †while 530.7 kb is formally
outside of the pre-defined cis-limit of 500 kb, the AGRP association was classified as cis-acting.
All other pQTL associations were either acting across chromosomes or at distances more than
100 MB.
(PDF)
Novel loci for the plasma proteome
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1006706 April 3, 2017 16 / 21
S2 Table. Pleiotropy of reported trait protein SNPs with findings from previously pub-
lished GWAS studies. Publically available studies were investigated and associations were
reported for proxy SNPs with r2 LD above 0.6 and association P-value stronger than 5e-8.
Other trait–the trait investigated in the published GWAS; Other SNP–the index SNP in the
published GWAS; r2 (EUR 1000G)–linkage disequilibrium between Olink-improve study
index SNP and the other SNP; Other P-value–P-value as reported in published GWAS;
Pubmed ID–the pubmed ID of the published GWAS; Olink SNP–the index SNP of the Olink-
improve study; Olink Trait Protein–the trait protein associated in the Olink-improve study;
Olink P-value–the P-value as also reported in Table 1.
(PDF)
S3 Table. Overview of all 92 measured proteins, with quality control parameters, descrip-
tive statistics and heritability estimates. All descriptive statistics are reported on the log10--
transformed data that was used for analysis; #samples below LOD–the number of samples
below limit of detection; CV%—coefficient of variation; Included–final choice on inclusion in
analysis; Mean (SD)–mean and standard-deviation; Median (IQR)–median and inter-quartile
range; V(G)/Vp–The GCTA calculated narrow-sense heritability, given as estimate ± standard
error (P-value). Note also that negative heritability estimates are reported as 0%, reflecting esti-
mate artefacts down to -4.30%. When applying the algorithm to imputed data, it fails for 37 of
83 proteins.
(PDF)
S1 Dataset. Overview of standard curves for all proteins measured with the olink-platform.
(XLSX)
S1 Text. Membership of the IMPROVE study group.
(DOCX)
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